Fernanda I Staquicini Selected Research

1-(1-mercaptocyclohexaneacetic acid)-2-(O- methyl-L-tyrosine)-8-L-arginine- vasopressin (AAVP)

3/2021	Design and proof-of-concept for targeted phage-based COVID-19 vaccination strategies with a streamlined cold-free supply chain.
1/2020	Targeted AAVP-based therapy in a mouse model of human glioblastoma: a comparison of cytotoxic versus suicide gene delivery strategies.
11/2016	Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes.
11/2016	Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer.
3/2008	A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fernanda I Staquicini Research Topics

Disease

19	Neoplasms (Cancer) 07/2021 - 01/2006
3	Breast Neoplasms (Breast Cancer) 07/2021 - 11/2016
3	Prostatic Neoplasms (Prostate Cancer) 11/2016 - 07/2015
3	Neoplasm Metastasis (Metastasis) 11/2016 - 10/2008
2	COVID-19 03/2021 - 01/2021
2	Glioblastoma (Glioblastoma Multiforme) 01/2020 - 01/2011
2	Lung Neoplasms (Lung Cancer) 01/2016 - 03/2015
1	Iron-Deficiency Anemia (Anemia, Iron Deficiency) 07/2021
1	Severe Acute Respiratory Syndrome 03/2021
1	Triple Negative Breast Neoplasms 01/2021
1	Brain Neoplasms (Brain Tumor) 01/2011
1	Carcinogenesis 09/2010
1	Melanoma (Melanoma, Malignant) 10/2008
1	Sarcoma (Soft Tissue Sarcoma) 03/2008
1	Herpes Simplex 03/2008

Drug/Important Bio-Agent (IBA)

13	LigandsIBA 03/2021 - 01/2006
6	Peptides (Polypeptides)IBA 03/2021 - 01/2006
5	1-(1-mercaptocyclohexaneacetic acid)-2-(O- methyl-L-tyrosine)-8-L-arginine- vasopressin (AAVP)IBA 03/2021 - 03/2008
5	Pharmaceutical PreparationsIBA 02/2016 - 01/2006
3	Endoplasmic Reticulum Chaperone BiPIBA 01/2018 - 11/2016
3	Monoclonal AntibodiesIBA 01/2018 - 10/2008
3	Proteins (Proteins, Gene)FDA Link 01/2017 - 01/2006
3	Thymidine KinaseIBA 11/2016 - 03/2008
2	IronIBA 07/2021 - 01/2011
2	VaccinesIBA 03/2021 - 01/2021
2	IntegrinsIBA 01/2020 - 11/2011
2	Annexin A2 (Annexin II)IBA 01/2017 - 11/2011
2	Biomarkers (Surrogate Marker)IBA 11/2016 - 07/2015
2	Peptide LibraryIBA 11/2011 - 01/2006
1	Ferrosoferric Oxide (Magnetite)FDA Link 07/2021
1	Contrast MediaIBA 07/2021
1	Cyclic PeptidesIBA 01/2021
1	CytokinesIBA 01/2021
1	Calcitriol Receptors (Calcitriol Receptor)IBA 01/2021
1	Protein Disulfide-IsomerasesIBA 01/2021
1	Eph Family Receptors (Eph Receptors)IBA 01/2020
1	AntibodiesIBA 01/2018
1	Immunoconjugates (Immunoconjugate)IBA 01/2018
1	Ganciclovir (Cytovene)FDA LinkGeneric 11/2016
1	ProdrugsIBA 11/2016
1	Small Interfering RNA (siRNA)IBA 11/2016
1	Cell Surface ReceptorsIBA 11/2016
1	Immunoglobulin FragmentsIBA 11/2016
1	HydrogelsIBA 02/2016
1	Silicon Dioxide (Silica)FDA LinkGeneric 02/2016
1	Liposomes (Liposome)IBA 02/2016
1	Interleukin-11 Receptors (Interleukin 11 Receptor)IBA 01/2016
1	bone metastasis-targeting peptidomimetic-11IBA 01/2016
1	AntigensIBA 07/2015
1	Long Noncoding RNAIBA 07/2015
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 03/2015
1	CD13 Antigens (Alanine Aminopeptidase)IBA 01/2012
1	Metalloproteases (Metalloproteinases)IBA 01/2012
1	Annexin A4IBA 11/2011
1	Cathepsin BIBA 11/2011
1	Myeloblastin (Proteinase 3)IBA 11/2011
1	Apolipoprotein E3IBA 11/2011
1	ProhibitinsIBA 11/2011
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 10/2008
1	CD146 AntigenIBA 10/2008

Therapy/Procedure

7	Therapeutics 01/2020 - 03/2008
2	Precision Medicine 01/2021 - 11/2016
1	Aftercare (After-Treatment) 01/2020
1	Castration 11/2016
1	Radiotherapy 03/2015